A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of CND261 in Patients with Seropositive Rheumatoid Arthritis

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523265-15-00

Acronym

CND261-101

Enrollment

Registered

2025-12-16

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seropositive Rheumatoid Arthritis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Romania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026